ACB Stock Alert: What to Know as Curaleaf Announces Takeover Bid for Aurora Cannabis

Aurora Cannabis (ACB) stock soared on Aug. 11 after U.S. multi-state operator Curaleaf (CURLF) announced plans to launch an unsolicited takeover bid. 

Curaleaf has already formed a special committee to review its $4 per share cash-and-stock proposal, which it intends to take directly to ACB shareholders after private acquisition talks stalled. 

Despite the recent surge, Aurora Cannabis shares are still down about 10% versus the start of this year. 

Why Is Curaleaf Willing to Pay a Premium for ACB Stock?

Curaleaf is willing to pay a significant premium for ACB shares as the acquisition would accelerate its international expansion, particularly across European medical markets such as Germany, Poland, and the UK. 

Bringing Aurora Cannabis under its umbrella will grant CURA access to premier EU-GMP certified cultivation facilities, including the recently acquired Safari Flower Company, adding over 50 tons of annual production capacity.

All in all, combining the two companies would create a global powerhouse spanning 17 countries, generating over $1.5 billion in annual revenue and at least $40 million in annual cost synergies. 

Note that Curaleaf stock also ended about 6% higher on Tuesday after announcing plans to go after Aurora Cannabis. 

Is There Any Further Upside Left in Aurora Cannabis Shares?

Aurora Cannabis shares are currently hovering around $3.48, which still signals a discount to the per-share price that Curaleaf is willing to pay. This means there’s significant upside potential if the deal closes. 

Plus, Curaleaf may be forced to sweeten its offer, especially since Aurora’s board has highlighted that the proposed valuation cap falls below prices ACB traded at as recently as December 2025. 

Wall Street analysts have also noted that the current bid undervalues the cannabis firm’s long-term medical franchise, reinforcing that further upside could emerge from Curaleaf’s proposed acquisition of ACB.  

On the flip side, however, if Aurora rejects the unsolicited bid without securing a higher bid, shares could surrender recent gains. 

What’s the Consensus Rating on Aurora Cannabis?

Heading into Aug. 11, Wall Street had a consensus “Moderate Buy” rating on ACB stock, with price targets as high as $5.71.

This means that at least some analysts believe Aurora Cannabis could eventually be worth more as a standalone company than what Curaleaf has proposed to buy it for.